Latest Breaking News On - Rapport therapeutics - Page 5 : comparemela.com

Rapport Therapeutics raises $150M in funding to advance neuromedicine platform

Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds

Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company's platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.

Rapport Therapeutics Raises $150M in Series B Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointme

- Funding to support ongoing clinical programs in seizure and psychiatric disorders and precision neuromedicine discovery platform- Raymond Kelleher, M.D., Ph.D., of lead investor Cormorant Asset Management, and James Healy, M.D., Ph.D., of Sofinnova Investments, join Board of DirectorsBOSTON & SAN DIEGO (BUSINESS.

Rapport Therapeutics brings in $150M Series B funding round

Rapport Therapeutics raised $150 million in a Series B round nearly six months after it launched.